Bevacizumab for severe HHT liver issues with high heart output
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This study looks at how well the drug Bevacizumab works and how safe it is for people with HHT who have severe liver problems that cause their heart to pump too much blood. It aims to help doctors understand if this treatment can help manage these serious symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of hereditary hemorrhagic telangiectasia (HHT).
- You have been treated with Bevacizumab for severe liver problems caused by HHT that also affected your heart's pumping ability.
- You had a heart ultrasound or right heart catheterization within the 12 months before starting Bevacizumab.
- You are being cared for in a French HHT center and are registered in the national CIROCO HHT database.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for liver cancer that cannot be removed with surgery. It combines targeted therapy and immunotherapy with a procedure that delivers chemotherapy directly to the liver, aiming to shrink tumors and improve outcomes.
This trial tests a new drug called ATV-1601 in people with HHT, a genetic condition that causes abnormal bleeding and blood vessel problems. The drug aims to reduce bleeding and anemia caused by HHT.
This trial tests a drug injected directly into the brain's abnormal blood vessels to see if it can help people who can't have surgery or other standard treatments. It may reduce symptoms and prevent future bleeding.
This trial tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce bleeding in people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (bevacizumab) given through a vein or directly into the liver artery, along with standard chemotherapy directly into the liver artery, for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink or control the cancer.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.